We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+7.79%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$453M
AUM Growth
+$57.9M
Cap. Flow
+$54.8M
Cap. Flow %
12.09%
Top 10 Hldgs %
36.96%
Holding
92
New
18
Increased
38
Reduced
28
Closed
8

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$17.1M
2
HCA icon
HCA Healthcare
HCA
+$12.4M
3
CVS icon
CVS Health
CVS
+$12.3M
4
DHR icon
Danaher
DHR
+$4.2M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.94M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$7.39M
2
DXCM icon
DexCom
DXCM
+$7.21M
3
PODD icon
Insulet
PODD
+$5.03M
4
RCUS icon
Arcus Biosciences
RCUS
+$4.64M
5
CDMO
Avid Bioservices, Inc. Common Stock
CDMO
+$4.58M

Sector Composition

Rank Sector Weight
1 Healthcare 95.63%
2 Industrials 1.69%
3 Technology 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
26
AbbVie
ABBV
$439B
$7M 1.55%
51,722
-23,278
-31% -$2.75M
ANIP icon
27
ANI Pharmaceuticals
ANIP
$1.72B
$6.32M 1.4%
137,226
+51,880
+61% +$2.23M
GOSS icon
28
Gossamer Bio
GOSS
$87.3M
$6.18M 1.36%
546,421
-240,449
-31% -$2.86M
BCRX icon
29
BioCryst Pharmaceuticals
BCRX
$2.7B
$5.54M 1.22%
400,001
+298,040
+292% +$3.94M
RCUS icon
30
Arcus Biosciences
RCUS
$3.69B
$4.74M 1.05%
117,099
-119,538
-51% -$4.64M
PODD icon
31
Insulet
PODD
$10B
$4.52M 1%
17,000
-17,340
-50% -$5.03M
FULC icon
32
Fulcrum Therapeutics
FULC
$285M
$4.42M 0.98%
250,106
-88,690
-26% -$1.76M
MRVI icon
33
Maravai LifeSciences
MRVI
$869M
$4.13M 0.91%
98,688
+8,688
+10% +$352K
XRAY icon
34
Dentsply Sirona
XRAY
$2.26B
$4.1M 0.91%
73,566
-6,889
-9% -$379K
KROS icon
35
Keros Therapeutics
KROS
$218M
$4.09M 0.9%
+69,861
New +$3.48M
BCYC
36
Bicycle Therapeutics
BCYC
$289M
$3.94M 0.87%
64,800
-4,749
-7% -$262K
HBIO icon
37
Harvard Bioscience
HBIO
$28M
$3.79M 0.84%
53,708
+6,171
+13% +$439K
AZTA icon
38
Azenta
AZTA
$1.46B
$3.77M 0.83%
36,554
-3,446
-9% -$374K
STRO icon
39
Sutro Biopharma
STRO
$354M
$3.29M 0.73%
22,122
+5,783
+35% +$1.04M
THC icon
40
Tenet Healthcare
THC
$21.5B
$3.27M 0.72%
+40,000
New +$2.92M
SUPN icon
41
Supernus Pharmaceuticals
SUPN
$2.73B
$3.05M 0.67%
104,714
+4,299
+4% +$130K
KOD icon
42
Kodiak Sciences
KOD
$2.7B
$2.98M 0.66%
35,174
-1,528
-4% -$155K
RGEN icon
43
Repligen
RGEN
$9.39B
$2.74M 0.6%
10,331
-9,669
-48% -$2.6M
ATEC icon
44
Alphatec Holdings
ATEC
$1.48B
$2.69M 0.59%
234,923
-15,077
-6% -$178K
IMGO
45
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$2.61M 0.58%
+110,000
New +$2.55M
VCYT icon
46
Veracyte
VCYT
$3.59B
$2.56M 0.57%
62,264
+17,264
+38% +$763K
STXS icon
47
Stereotaxis
STXS
$138M
$2.56M 0.57%
413,218
-36,782
-8% -$220K
NRIX icon
48
Nurix Therapeutics
NRIX
$2.74B
$2.54M 0.56%
+87,824
New +$2.66M
IONS icon
49
Ionis Pharmaceuticals
IONS
$9.43B
$2.44M 0.54%
80,238
-56,142
-41% -$1.77M
MDGL icon
50
Madrigal Pharmaceuticals
MDGL
$12.4B
$2.43M 0.54%
28,670
-2,723
-9% -$224K
1
2
3 4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2021 Portfolio in Review

As of Q4 2021, Parkman Healthcare Partners held 92 positions worth $453M, up 15% from $395M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Parkman Healthcare Partners deployed $54.8M of net new capital in Q4 2021, opening 18 new positions and adding to 38 existing holdings. Its largest new stake was UnitedHealth: 37,823 shares worth $19M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was DexCom, an estimated $7.21M trimmed.

  • Parkman Healthcare Partners's largest Q4 2021 buy was UnitedHealth: 37,823 shares worth $19M.
  • Parkman Healthcare Partners added most to Danaher in Q4 2021, an estimated $4.2M increase.
  • Parkman Healthcare Partners's biggest Q4 2021 reduction was DexCom, cutting an estimated $7.21M.
  • Parkman Healthcare Partners fully exited Humana in Q4 2021, selling an estimated $7.39M.
  • Parkman Healthcare Partners's ten largest holdings make up 37% of its $453M portfolio in Q4 2021.
  • Parkman Healthcare Partners opened 18 new positions and closed 8 in Q4 2021.
  • Parkman Healthcare Partners's portfolio value rose 15% quarter-over-quarter to $453M.

Based on Parkman Healthcare Partners's 13F filing for Q4 2021, filed 11 Feb 2022.